SEAS study News
Most Popular SEAS study Story
More bad Vytorin news for Merck, Schering
Merck and Schering-Plough saw two more strikes leveled at their cholesterol combo med Vytorin yesterday. First, preliminary results from a new trial showed that Vytorin didn't benefit patients with... Read more...
Latest Headlines
- September 19, 2008
- September 5, 2008
- September 3, 2008
- September 2, 2008
- September 2, 2008
- August 22, 2008
- August 1, 2008
- July 25, 2008
- July 22, 2008
- July 21, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
